Technology Transfer

The Institute of Molecular Genetics of the Czech Academy of Sciences (IMG) since its foundation has maintained a strong tradition of linking excellent research with application of the results into practice. We keep long-term cooperation with dozens of research and industrial partners. Most of them are based abroad, but we also have a number of partners in the Czech Republic, and further development of our technologies has helped to establish more than half a dozen Czech spin-off companies, some of which have already successfully established themselves on the global market.

The Centre of Technology Transfer (CTT) seeks for applicable results and ensures protection of the IMG intellectual property. CTT helps IMG researchers to develop cooperation with the application sphere (commercial entities or state administration bodies) in the form of knowledge transfer or economic activity.

 

IMG technology transfer

 

 

Frequently asked questions

Why should I announce creation of a result?

IMG employees should announce the result whenever they believe that it could be used in practice in the future. Research results are usually in the very early stages of development and require significant investment before being launched on the market. The intellectual property protection following the Notice may be an incentive for commercial partners to make such an investment.
Notwithstanding the fact that the Notice is required by law, it is the duty of the IMG, as a recipient of public money, to ensure timely protection of intellectual property and the results arising from subsidies.

How do I submit a Notification?

Use the Notice form and follow the simple instructions. As soon as the IMG receives the Notice, it will inform you of the next steps.

Can I publish research results while protecting the value of my intellectual property?

Yes, but it is necessary to submit the Notice well in advance of any publication. Once the result is published, the invention may have limited or minimal potential for patent protection. Be sure to provide information about any immediate or prior presentation, lecture, poster, abstract, submission of a research proposal, dissertation, publication, or other public presentation of the invention in the Notice.

When and how can I announce creation of a research tool?

These are usually results such as antibodies, vectors, plasmids, cell lines, mice, and others used as “tools” in the research process. Research tools do not necessarily have to be protected by patents to be licensed to commercial third parties and to generate revenue for your laboratory. Additional research tools (such as new separation processes) may need to be patented for a company to invest in technical development to make the process widely applicable. If you possess research tools that you think are valuable, IMG will work with you to develop their appropriate protection, licensing and distribution strategy. We will also help you to distribute research materials at zero or minimal cost to other academic collaborators while maintaining the business potential of the materials.

Should I announce software as well?

Yes, software code licensing is possible based on various distribution strategies, for commercial development and distribution for non-commercial and / or academic purposes, etc., and can be practically usable and commercially successful. If you have software that you believe involves a patentable process, you should submit a Notification Form for the patentable process and submit the IMG software code.

Should I report contributions from inventors other than IMG?

All contributors to ideas leading to the invention should be listed in your Notice, even if they are not IMG employees. The CTT, together with a legal adviser, will determine the rights of these persons and institutions. It is sensible to discuss collaborations (preferably before they begin) with CTT to understand the implications for any subsequent inventions.

What are the rights of a research sponsor to discoveries related to my research?

The rights granted to research sponsors vary according to the contract concluded. See the Internal Intellectual Property Directive for more information.

What is considered a disclosure of the invention?

Everything that is easily accessible to the public (diary, conference presentations, publications on the web, Facebook, video on YouTube, even dissertations indexed in the library) and describes in sufficient detail the basic ideas that someone else would be able to create and use as invention; i.e., those ideas that are new.

 

Form – Research result (invention) disclosure Research result disclosure
Revenues from the knowledge transfer Revenues from the knowledge transfer
List of patents List of patents
Selected results (in Czech) Selected results (in Czech)

 

Total income (in thousands CZK), income per 1 employee according to FTE, and summary of applied results in the period 2011 – 2017

 

Parameter  2011 2012 2013 2014 2015 2016 2017
FTE* 187(292) 195(304) 204(326) 247 (311) 272 (329) 376 (333) 284 (335)
Income from national R&D funding 168 955 161 334 277 368 253 909 338 544 304 128 310 632
Income from international grants 14 916 936 5 093 3 059 8 961 6 649 23 823
Institutional funding 145 636 149 837 126 401 123 895 155 997 194 431 196 823
Contractual research and sale of R&D services 27 052 22 714 9 414 14 250 14 929 11 874 15 152
Total income 356 559 334 821 418 276 395 113 518 431 517 082 546 430
Total per 1 researcher** 1907(1221) 1717(1101) 2050(1283) 1600(1270) 1906(1576) 1375(1553) 1924(1631)

* In the parentheses, the numbers of the institute researchers are given.
For the purposes of this statistics, a researcher is an employee of category V1-V6, i.e., research assistant, PhD student, postdoctoral fellow, research fellow, scientist, and senior scientist.

** In the parentheses, the income per numbers of the Institute employees is given.

Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O, Ráliš J, Holčák P: Screening container for solid-state target.
Date of Model: 15.08.2016. Model Number: 29695. [IPO]

Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O, Holčák P: Automated microfluid system.
Date of Model: 19.07.2016. Model Number: 29648. [IPO]

Seifert D, Jelínek P, Marešová L, Sedláček J, Lebeda O: Mikrofluidní chemický čip pro značení monoklonálních protilátek radionuklidy.
Date of Model: 07.09.2015. Model Number: 28597. [IPO]

Hozák P, Šlouf M, Nebesářová J, Moša M, Krivjanská M: Assembly of mutually recognizable nanoparticles for multiple ultrastructural labeling.
Date of Model: 07.02.2011. Model Number: 21711. [ISVAV] [IPO]

Brynda J, Cígler P, Grüner B, Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M, Holub J, Dzubak P, Hajduch M: Inhibidores de anhidrasa carbónica y método de su producción.
Publication Date
: 28.06.2016. Application Number: PCT/CZ2012/000106. [OEPM]

Bartůněk P, Kořínek V, Pombinho A, Tůmová L: Monensin-containing pharmaceutical composition for the treatment of familiar adenomatous polyposis.
Date of Patent: 11.05.2016. Patent Number: 306011. [IPO]

Havlík M, Kaplánek R, Dolenský B, Rak J,  Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Asymmetric Troger bases with hydrazone group and their use in the treatment of oncologic diseases.
Date of Patent: 23.12.2015. Patent Number: 305683. [IPO]

Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Dioxocyclobutenyl hydrazones and their anticancer activity.
Date of Patent: 02.12.2015. Patent Number: 305626. [IPO]

Kaplánek R, Jakubek M, Havlík M, Rak J,  Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J, Král V: Caffeine-8-hydrazones as novel cytostatics for the treatment of oncologic diseases .
Date of Patent: 02.12.2015. Patent Number: 305625. [ISVAV] [IPO]

Rak J, Kaplánek R, Štulcová T, Drašar P, Havlík M, Bříza T, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J,  Král V: Cholyl hydrazones and their use in the treatment of tumor and leukemia diseases.
Date of Patent: 25.11.2015. Patent Number: 305607. [IPO]

Kaplánek R, Bříza T, Havlík M, Rak J, Kejík Z, Džubák P, Hajdúch M, Konečný P, Štěpánková J, Králová J,  Král V: Benzothiazole- substituted cyclobut-3-ene-1, 2-dione-3-hydrazones and their use in the treatment of various types of leukemia and tumor diseases.
Date of Patent: 14.10.2015. Patent Number: 305538. [IPO]

Kaplánek R, Havlík M, Rak J, Králová J,  Král V: Troger base derivatives and cytostatic properties thereof.
Date of Patent: 16.09.2015. Patent Number: 305488. [ISVAV] [IPO]

Grekov I, Pombinho A,  Šíma M, Kobets T, Bartůněk P, Lipoldová M: Pharmaceutical composition containing diphenyleneiodonium for treating diseases caused by parasites of Trypanosomatidae species.
Date of Patent: 20.05.2015. Patent Number: 305247. [ISVAV] [IPO]

Král V, Králová J, Martásek P, Bříza T, Kejík Z: Use of polymethine salts as sensors for tumor markers.
Date of Patent: 29.12.2014. Patent Number: 304948. [ISVAV] [IPO]

Flieger M, Stodůlková E, Kolařík M, Man P, Černý J, Císařová I, Králová J: Submersible strains Quambalaria sp. CCM 8372 and CCM 8373, mixture of naphthoquinone dyes produced thereby, method of their production and use .
Date of Patent: 29.01.2014. Patent Number: 304335. [ISVAV] [IPO]

Hozák P, Šlouf M, Nebesářová J, Moša M, Krivjanská M: Set of mutually recognizable nanoparticles, process of their preparation as well as their use for multiple ultra-structural identification.
Date of Patent: 18.12.2013. Patent Number: 304250. [ISVAV] [IPO]

Rak J, Kaplánek R, Král V, Králová J, Štulcová T, Drašar P: Conjugates of hydrazones with cholic acid as novel cytostatics.
Date of Patent: 18.09.2013. Patent Number: 304112. [IPO]

Král V, Bříza T, Kejík Z, Králová J, Rimpelová S, Ruml T, Martásek P: Use of polymethine salts as mitochondrial probes.
Date of Patent: 05.09.2013. Patent Number: 304094. [ISVAV] [IPO]

Brynda J, Cígler P, Grüner B,  Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M, Holub J, Dzubak P, Hajduch M: Carbonic anhydrase inhibitors and method of their production.
Publication Date: 02.05.2013. Application Number: PCT/CZ2012/000106. [USPTO]

Brynda J, Cígler P, Grüner B,  Řezáčová Maloy P, Mader P, Šícha V, Bakardjiev M: Carbonic anhydrase inhibitors and process for their preparation.
Publication Date: 02.05.2013. Application Number: 2011-676. [IPO]

Kaplánek R, Rak J, Král V, Králová J: Phathalazin-1-ylhydrazones and their use in the treatment of tumor diseases.
Date of Patent: 06.03.2013. Patent Number: 303748. [ISVAV] [IPO]

Novák P, Sedlák D, Bartůněk P, Kotora M: Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them.
Date of Patent: 18.12.2012. Patent Number: US8334280. [ISVAV]

Rejman D, Pohl R, Bartůněk P, Ribeiro Pombinho A, Krasny L, Latal T: Lipophosphonoxins, method of their preparation and use.
Publication Date: 28.11.2012. Application Number: 2012-169491. [ISVAV] [IPO]

Rejman D, Pohl R, Bartůněk P, Riberio Pombinho Antonio José, Krásný P, Látal T: Lipophosphonoxins, their preparation and use.
Date of Patent: 31.10.2012. Patent Number: 303569. [ISVAV] [IPO]

Smetana K, Dvořánková B, Lacina L, Strnad H, Kolář M, Chovanec M, Plzák J, Čada Z, Vlček Č, Szabo P, Betka J, Motlík J, Kovářová H, Jarovská K: Combination of antibodies or their Fab fragments for use as drugs and pharmaceutical compositions containing these antibodies or fragments thereof.
Date of Patent: 25.04.2012. Patent Number: 303227. [ISVAV] [IPO]

Smetana K, Dvořánková B, Lacina L, Strnad H, Kolář M, Chovanec M, Plzák J, Čada Z, Vlček Č: Combination of monoclonal antibodies or their Fab fragments for use as drugs and pharmaceutical compositions containing these antibodies or fragments thereof.
Date of Patent: 17.03.2010. Patent Number: 301597. [ISVAV] [IPO]

Novák P, Sedlák D, Bartůněk P, Kotora M: Ligands of estrogen receptors α and β, method of their preparation, and pharmaceuticals comprising them.
Publication Date
: 12.11.2009. Application Number: 2009-741723. [ISVAV] [IPO]

Hejnar J, Šenigl F: Regulatory promoter/enhancer element protected from DNA methylatian and transcriptional silencing.
Date of Patent: 26.03.2009. Patent Number: 300377. [ISVAV] [IPO]

Král V, Bříza T, Kejík Z, Králová J, Poučková P: Use of multimodal systems for preparation of therapeutic and diagnostic tools for management of malignant diseases.
Date of Patent: 02.02.2009. Patent Number: 300197. [ISVAV] [IPO]

Selected results of cooperation with commercial sphere and other organizations obtained during implementation of IMG projects in the years 2010 - 2013

License agreement with company Seattle Genetics (for cDNA encoding a specific monoclonal antibody). Application: construction of a potential therapeutic product
Aptamer inhibiting the enzymatic activity of Taq DNA polymerase. Application: Prototype kit for Hot start PCR with aptamer inhibiting the Taq DNA polymerase enzymatic activity. Supported by Technological Agency of the Czech Republic, partner organization:Top-Bio, s.r.o.
Experimental development of multimodal holographic microscope – revolutionary prototype of a microscope based on incoherent holography. Partner organizations contributing to the project: TESCAN, a.s., Technical Institute in Brno (VUT)
Utilization of nanofibre carriers to transport stem cells for medical purposes. Result obtained during implementation of project Biocompatible nanofibre scaffolds forming novel drug matrices for the application of biologically and pharmacologically active substances. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i.
Recombinant Strep-TRItag-TRAIL expression plasmid for selective precipitation of TRAIL-TRAIL-R complexes. Preparation and characterization of monoclonal antibody against cytoskeletal protein NFH. Preparation and characterization of monoclonal antibodies recognizing human protein Abraxas-1. Plasmids expressing recombinant proteins hAPP-IgG and hAPLP2-IgG. Preparation and characterization of human protein LGR5 and polyclonal antibodies recognizing human protein LGR5. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by companies Exbio Praha a.s. and Apronex, s.r.o. Collaborating partners: Institute of Microbiology AS CR, v. v. i., Faculty of Science, Charles University Prague; companies Exbio Praha a.s., Apronex s.r.o.
Preparation of monoclonal antibodies against proteins CLIC5a, LARGE and OPAL1. Results obtained in implementing the project “Centre for Molecular and Cellular Immunology”. These results are applied in practice by company Apronex s.r.o. Collaborating partners: 2nd Faculty of Medicine, Charles University Prague; company Apronex s.r.o.
Fifteen hybridoma cell lines prepared as part of the project “Structure and Disorders of the Cell Nucleus Nucleoskeleton – Identification and Diagnostics”. Collaborating partner: company KRD s.r.o.
Nanoparticles conjugated with antibodies of hybridoma cell lines 2E3-41, 3B6-3, 4C6-37, 5G3-51, 6B4-56, 6B4-57, 6D6-16 a 6D6-34, prepared as part of the project “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.
Construction of nanofibre carriers with incorporated cyclosporin A and carrying stem cells for therapeutic purposes. Result obtained during implementation of project “Biocompatible Nanofibre Scaffolds Forming Novel Drug Matrices for the Application of Biologically and Pharmacologically Active Substances”. Collaborating partners: company Elmarco s.r.o., Institute of Experimental Medicine AS CR, v. v. i., Institute of Macromolecular Chemistry AS CR, v. v. i.
Novel universal qPCR mixes. Result obtained during implementation of project “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o.
Novel method for establishment of low protein concentrations in complex biological fluids using nano-iPCR. Result obtained during implementation of project: “Nano-PCR, Ultrasensitive Test for Detection of Specific Proteins in Body Fluids”. Collaborating partners: 3rd Faculty of Medicine, Charles University in Prague, Psychiatric Centre Prague, companies Vidia, s.r.o., Top-Bio s.r.o.
Certified methodology – Qualitative proof of viral vaccine antigens. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company SEVAPHARMA a.s.
Monoclonal antibodies 2E3.H3.F2, 4C6.D12.D2, 5G3.E1.G9, 5G3.E5.A8 a 6B4.E9.B4 conjugated with golden rods. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.
Monoclonal antibodies 2E3.H3.F2, 3B6.0.C7, 4C6.D12.D2, 5G3.E5.A8, 6B4.E9.B4, 6B4.E9.B6, 6B4.E9.B12 a6D6.F10.D12 conjugated with cubic palladium nanoparticles. Result obtained during implementation of project: “Novel Nanoparticles for Ultrastructural Diagnostics”. Collaborating partner: company Central European Biosystems s.r.o.

 

Applied research with participation of IMG researchers (mostly in collaboration with biotech companies) possesses clear economic potential. In the past 15 years, the IMG employees founded seven spin-off biotech companies, which operate independently and develop dynamically. Detailed information on these companies is mentioned below:

Apronex s.r.o.
http://www.apronex.cz/
Focused on research, development and production of biologically active recombinant proteins.
Cellvia s.r.o. Focused on development of small molecule-based drugs; activities are still at the launching phase.
EXBIO Praha a.s.
http://www.exbio.cz/
Focused on research, development and production of monoclonal antibodies and recombinant.
Proteix s.r.o.
http://www.proteix.cz/
Focused on research, development and production recombinant proteins.
Top-Bio s.r.o.
http://www.top-bio.cz/
Focused on development and production of reagents for DNA fragment amplification by polymerase chain reaction.

In the past 15 years, more than 150 commercially exploited hybridoma cell lines and plasmid constructs for preparation of recombinant proteins have been produced and transferred to implementation partners (Exbio, Apronex, Top-Bio) on contractual basis.

The total commercial turnover based on these products in the past 15 years was more than CZK 200 millions.

The Outcomes of TACR Projects - GAMA Programme

  • SGIP1 transgenic mice as a model of obesity and diabetes mellitus 2 (SGIP1 KI mice). [PDF]
  • Monoclonal antibody to TPX2 for cancer diagnosis. [PDF]
  • Panel of monoclonal antibodies to GCP2 for cancer diagnosis. [PDF]
  • Hybrid Twa DNA polymerase with enhanced enzymatic activity. [PDF]
  • Detection kit for autoantibodies against enteric alpha-­defensins. [PDF]
  • New compound with effect against parasite Leishmania. [PDF]
  • TP enhancer for sensitive RT-PCR. [PDF]
  • Multiplex analysis of released cytokines and their measurements in small volumes. [PDF]
  • Temperature-sensitive DNA aptamer blocking enzymatic activity of Twa DNA polymerase. [PDF]
  • Novel approach to labelling recombinant fragments of antibodies with copper radionuclides for PET imaging. [PDF]
  • ELISA test for gamma-tubulin detection in cancer diagnosis. [PDF]
  • Development of a probe for detection of PPM1D amplification in breast cancer samples. [PDF]

To get more information about these projects, patents or licences available please contact Center for Technology Transfer, IMG ASCR, Vídeňská 1083, 142 20 Prague 4, Czech Republic.

Phone: +420 241 063 227, +420 602 892 876
E-mail:
ctt@img.cas.cz

Last change: October 8, 2020